Cannabinoïdes

Cannabichromenic acid is a non-psychoactive phytocannabinoid and a precursor of cannabichromene1 which toxicological and pharmacological properties are unknown. Due to its structural similarity to cannabichromene, it is thought to reportedly exert anti-analgesic and anti-inflammatory activity.

Anandamide is an endogenous cannabinoid, which is a bioactive lipid mediator primarily found in the brain and peripheral organs. It is synthesized from membrane phospholipid precursors through enzymatic pathways, primarily involving the enzyme N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD). Anandamide acts as a ligand for cannabinoid receptors, mainly the CB1 receptor located in the central nervous system, and the CB2 receptor found in peripheral tissues.

Cannabigerovarinic acid is a phytocannabinoid and the precursor to tetrahydrocannabivarinic acid, cannabidivarinic acid, and cannabichromevarinic acid1. No in vitro or in vivo pharmacological and toxicological studies have been conducted on cannabigerovarinic acid.

1,2,3,9-Tetrahydro-4H-carbazol-4-one is a cyclic ketone compound, which can be synthesized through various organic reactions involving appropriate precursors. It is often derived from indole-based substrates through catalytic hydrogenation, allowing the formation of its stable tetrahydro structure with a retained core carbazole skeleton.

2-Arachidonyl glycerol is an endogenous cannabinoid receptor agonist, which is derived from arachidonic acid present in cellular membranes. It functions as a signaling lipid and plays a critical role in the endocannabinoid system, which is a complex network of receptors and ligands involved in maintaining physiological homeostasis.

AEF0117 is a signaling inhibitor of CB1-SSi that inhibits cannabinoid self-administration and can be used to study cannabis withdrawal.

Cannabichromevarin is a phytocannabinoid naturally found in very low levels compared to other cannabinoids from which it differs in having a propyl chain in place of a pentyl chain1. Based on its structure, it is believed to act as a potent anandamine inhibitor similarly to cannabichromene, however, the majority of its pharmacological and toxicological properties are currently unknown. In vitro assays have shown cannabichromevarin protect against oxidative stress in vitro in macrophages2. It was recently shown to be effective for treatment-resistant epilepsy in a patented combination with cannabidiol in a recent open-ended clinical trial3.